Drug Disc. and Pharma. Analysis: New Test Available for Faster Results in Diagnosis of Sepsis
Apr 05 2006 Read 5534 Times
The LightCycler SeptiFast test, a new rapid and reliable test for the detection and identification of 25
different sepsis-causing pathogens. The test, which has been developed by Roche Diagnostics, is the world's first PCR-based test of this kind, and can successfully recognise the infectious pathogens
responsible for approximately 90% of all sepsis cases.
Over 23,000 patients in the UK develop severe sepsis each year and with a hospital mortality rate of 45%, for over 10,000 of these people it proves fatal. This equates more than 27 deaths per day. Despite
improvements in its medical management, sepsis still constitutes one of the greatest challenges in intensive care medicine, with up to 26% of patients being given inappropriate treatment.
The LightCycler SeptiFast test has the major advantage of being able to detect and identify both bacterial and fungal sepsis pathogens in less than six hours. This offers a significant improvement over the
traditional blood culture methods which can take up to two to five days and even then there is a positive test rate of less than 20% for patients with sepsis. This is an important time saving for targeted
medical treatment, as only after pathogens are correctly identified can targeted therapy using a specific antibiotic begin.
different sepsis-causing pathogens. The test, which has been developed by Roche Diagnostics, is the world's first PCR-based test of this kind, and can successfully recognise the infectious pathogens
responsible for approximately 90% of all sepsis cases.
Over 23,000 patients in the UK develop severe sepsis each year and with a hospital mortality rate of 45%, for over 10,000 of these people it proves fatal. This equates more than 27 deaths per day. Despite
improvements in its medical management, sepsis still constitutes one of the greatest challenges in intensive care medicine, with up to 26% of patients being given inappropriate treatment.
The LightCycler SeptiFast test has the major advantage of being able to detect and identify both bacterial and fungal sepsis pathogens in less than six hours. This offers a significant improvement over the
traditional blood culture methods which can take up to two to five days and even then there is a positive test rate of less than 20% for patients with sepsis. This is an important time saving for targeted
medical treatment, as only after pathogens are correctly identified can targeted therapy using a specific antibiotic begin.
Digital Edition
Lab Asia August 2019
August 2019
In this Issue Articles Mass Spectrometry & Spectroscopy 67th ASMS Conference on Mass Spectrometry and Allied Topics Chromatography Using Gas Chromatography for measuring atmo...
View all digital editions
Events
ACS National Meeting & Expo, Fall 2019
Aug 25 2019 San Diego, CA, USA
Sep 01 2019 Berlin, Germany
Sep 03 2019 Manchester, UK
Sep 04 2019 Chiba City, Japan
Sep 08 2019 Krakow, Poland
Reader comments
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.